The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Thrombosis is a relatively common and potentially life-threatening complication of myeloproliferative neoplasms (MPN). The introduction of JAK inhibitors (JAKi) has had a profound effect upon the therapeutic landscape for MPN, however, potential effects of these drugs upon thrombotic risk is largely